|
T2649 |
Menin-MLL inhibitor MI-2
|
Menin-MLL Inhibitor,MI2,MI-2,Menin-MLL inhibitor 2,MI 2 |
Apoptosis
,
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
Menin-MLL inhibitor MI-2 (MI2) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM. |
|
T9399 |
Menin-MLL inhibitor 20
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
Menin-MLL inhibitor 20 is an irreversible inhibitor of menin-MLL interaction with antitumor activities. |
|
T2643 |
MI-3
|
Menin-MLL Inhibitor,Menin-MLL inhibitor 3,MI 3 |
Apoptosis
,
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
MI-3 (Menin-MLL Inhibitor) (Menin-MLL Inhibitor) is an effective inhibitor of Menin-MLL interaction (IC50: 648 nM). |
|
T69629 |
M‑89 MLL inhibitor
|
|
|
|
M‑89 is a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein−Protein Interaction (Kd = 1.4 nM; IC50 = 25nM). M-89 binds to menin with a Kd value of 1.4 nM and effectively engages cellular men... |
|
T12002 |
Menin-MLL inhibitor 4
|
|
Others
|
|
Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction . |
|
T79737 |
Menin-MLL inhibitor 29
|
|
Epigenetic Reader Domain
|
|
Menin-MLL Inhibitor 29 (Compound C1) is a Menin-MLL protein-protein interaction (PPI) inhibitor that demonstrates high affinity to Menin with a dissociation constant (K D) of 138 nM and impedes Menin's interaction with M... |
|
T78151 |
Bleximenib oxalate
|
Menin-MLL inhibitor 24 oxalate |
Epigenetic Reader Domain
|
|
Menin-MLL Inhibitor 24 (compound A) oxalate, a menin-mixed-lineage leukemia 1 (menin-MLL) inhibitor, is utilized in cancer research [1]. |
|
T72360 |
Menin-MLL inhibitor 26
|
|
|
|
Menin-MLL inhibitor 26 is a Menin-MLL inhibitor. Menin-MLL inhibitor 26 also is an active reference. Menin-MLL inhibitor 26 can inhibits cell growth. Menin-MLL inhibitor 26 can be used for the research of leukemia . |
|
T79117 |
Menin-MLL inhibitor 27
|
|
Epigenetic Reader Domain
|
|
Menin-MLL inhibitor 27 effectively inhibits the interaction between Menin and MLL, serving as a potential tool in cancer research, particularly for acute myeloid leukemia (AML) [1]. |
|
T3082 |
SGC0946
|
|
Histone Methyltransferase
|
|
SGC0946 is a highly effective and specific DOT1L methyltransferase inhibitor (IC50: 0.3 nM); selectively kill mixed lineage leukemia cells. |
|
T72135 |
(1s,4s)-Menin-MLL inhibitor-23
|
|
|
|
(1s,4s)-Menin-MLL Inhibitor-23, an enantiomer of Menin-MLL Inhibitor-23 (Example 99A), functions as an inhibitor of the menin-MLL interaction [1]. |
|
T8838 |
CCI-007
|
|
Apoptosis
,
Histone Methyltransferase
|
|
CCI 007 is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia with IC50 of 3.5 uM against MLL-r leukemia cell line PER-485 |
|
T12943 |
SNDX-5613
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
SNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM). SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias. |
|
T13336 |
VTP50469
|
|
Apoptosis
,
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
VTP50469 is a highly selective and orally active inhibitor of Menin-MLL interaction( Ki: 104 pM) and has potently anti-leukemia activity. |
|
T6916 |
OICR-9429
|
OICR 9429 |
Histone Methyltransferase
,
JAK
|
|
OICR-9429 is a potent antagonist of the interaction that WDR5 effect with peptide regions of MLL and Histone 3. It reduces the viability of acute myeloid leukemia cells in vitro. |
|
T28036 |
MI-2-2
|
MI22,MI 2 2 |
Histone Methyltransferase
|
|
MI-2-2 is an inhibitor of bivalent protein-protein interaction between menin and MLL with an IC50 of 46 nM. MI-2-2 binds to menin with Kd of 22 nM. |
|
T69628 |
Iptacopan hydrochloride hydrate
|
|
|
|
Iptacopan hydrochloride hydrate is a highly potent and highly selective factor B inhibitor. |
|
T69581 |
NVS MLLT-1
|
|
|
|
NVS-MLLT-1 is a selective inhibitor of YEATS domain of MLLT1 and MLLT3. |
|
T12886 |
SGC-iMLLT
|
|
Histone Methyltransferase
|
|
|
|
TQ0069 |
MI-503
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
MI-503 is a highly effective and orally bioavailable inhibitor of the menin-mLL interaction. |
|
T11925 |
M‑89
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
M-89, a highly potent and specific inhibitor of the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction, exhibits a Kd of 1.4 nM for menin binding. This compound holds potential for treating MLL leukemia... |
|
T16072 |
MI-538
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
MI-538 is an interaction between menin and MLL fusion proteins inhibitor(IC50 of 21 nM). |
|
T10706 |
CCI-006
|
|
Mitochondrial Metabolism
|
|
CCI-006, a selective inhibitor and chemosensitizer for MLL-rearranged leukemia cells, disrupts mitochondrial respiration. This action leads to irreversible mitochondrial depolarization and triggers a pro-apoptotic unfold... |
|
TQ0058 |
MI-463
|
|
Epigenetic Reader Domain
,
Histone Methyltransferase
|
|
MI-463 is a potent and orally bioavailable inhibitor of the menin-mLL interaction (IC50: 15.3 nM). |
|
T77339 |
BRD4-IN-4
|
|
Epigenetic Reader Domain
|
|
BRD4-IN-4 is a selective BRD4 inhibitor with an IC50 value of 6.83 μM for BRD4.BRD4-IN-4 selectively inhibits the proliferation of the MV4-11 cell line and arrests the cells in G1 phase.BRD4-IN-4 can be used to study MLL... |
|
T8768 |
MM-102 TFA
|
HMTase Inhibitor IX TFA |
Histone Methyltransferase
|
|
MM-102 TFA (HMTase Inhibitor IX TFA) is a potent WDR5/MLL interaction inhibitor, achieves IC50 = 2.4 nM. MM-102 compound prevents the interaction between mixed lineage leukemia 1 (MLL1) and WD Trp-Asp repeat domain 5 (WD... |
|
T4247 |
I-CBP112 hydrochloride
|
|
Epigenetic Reader Domain
|
|
I-CBP112 is a selective inhibitor of the bromodomain-containing transcription factors. I-CBP112 (1 mM) has little activity against other bromodomains. I-CBP112 targets the CBP/p300 bromodomains. I-CBP112 significantly re... |
|
T6889 |
MI-136
|
|
Apoptosis
,
Epigenetic Reader Domain
,
Androgen Receptor
|
|
MI-136 inhibits expression of androgen receptor (AR) target genes that DHT induced. |
|
T6333 |
MM-102
|
MM102,HMTase Inhibitor IX |
Histone Methyltransferase
|
|
MM-102 (HMTase Inhibitor IX) is a high-affinity peptidomimetic MLL1 inhibitor with IC50 of 0.4 μM. |
|
T39937 |
M-808
|
|
|
|
M-808 is a potent and efficacious covalent inhibitor, targeting the interaction between Menin and MLL. It demonstrates a high binding affinity with an IC50 value of 2.6 nM. |
|
T24484 |
ML399
|
VU-0516340,VU 0516340,ML-399,VU0516340,ML 399 |
|
|
ML399 is the menin-- MLL interaction inhibitor that acts by demonstrating strong and selective effects in MLL leukemia cells and validating specific mechanism of action. |
|
T15831 |
M-525
|
|
Others
|
|
M-525 binds to menin (IC50: 3 nM) and achieves low nanomolar potencies in cell growth inhibition and in the suppression of MLL regulated gene expression in MLL leukemia cells. M-525 is a first-in-class, highly potent, ir... |
|
T22978 |
MI-2 (hydrochloride)
|
|
Others
|
|
MI-2 (Menin-MLL Inhibitor) is an effective menin-MLL interaction inhibitor (IC50: 446 ± 28 nM). |
|
T69624 |
TC-5115
|
|
|
|
TC-5115 is a potent inhibitor of MLL methyltransferase with IC50 value of 16 nM. TC-5115 may lead to the development of a new therapy for the treatment of human MLL leukemia. The mixed-lineage leukemia (MLL) protein, al... |
|
T24472 |
MIV-6R
|
MIV6R,VU05163101,VU0516310-1,VU0516310 1,MIV 6R |
|
|
MIV-6R is an inhibitor of the menin- MLL interaction that acts by demonstrating strong and selective effects in MLL leukemia cells and validating specific mechanisms of action. |
|
T12091 |
MM-589
|
|
JAK
|
|
MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction. |
|
T27134 |
DCYM21
|
DC YM 21,DC-YM21,DCYM-21,DC_YM21,DC YM21 |
|
|
DCYM21 is an inhibitor of menin-MLL interaction. DCYM21 demonstrates potent and selective blockage of proliferation and induces both cell cycle arrest and differentiation of leukemia cells harboring MLL translocations. |
|
T13336L |
VTP50469 fumarate
|
|
Others
|
|
VTP50469 fumarate is a highly selective and orally active inhibitor of Menin-MLL interaction (Ki: 104 pM), and has potently anti-leukemia activity. |
|
T61735 |
MI-1
|
|
|
|
MI-1 inhibits Menin-MLL interaction with an IC 50 of 1.9 μM [1]. |
|
T24463 |
MI-1481
|
MI 1481 |
|
|
MI-1481 is an effective MML1 inhibitor (IC50: 3.6 nM). MI-1481 showed very potent inhibition of the menin-MLL1 interaction (IC50: 3.6 nM). MI-1481 also demonstrates pronounced activity in MLL leukemia cells and in vivo i... |
|
T82598 |
DDO-2213
|
|
|
|
DDO-2213 is a potent, orally active inhibitor of the WDR5-MLL1 interaction, demonstrating an IC50 of 29 nM and a Kd of 72.9 nM against WDR5. It selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase ... |
|
T12091L |
MM-589 TFA
|
|
JAK
|
|
MM-589 TFA is a potent WD repeat domain 5 (WDR5)inhibitor and mixed lineage leukemia (MLL) protein-protein interaction. |
|
T12290 |
OICR-0547
|
|
Others
|
|
OICR-0547 is a closely related derivative of OICR-9429. OICR-9429 is a novel small-molecule Wdr5-MLL interaction antagonist. |
|
T39938 |
M-1211
|
|
|
|
M 1121 is a covalent and orally active inhibitor of the menin-MLL interaction capable of achieving complete and persistent tumor regression. |
|
T39585 |
Ziftomenib
|
KO-539 |
Histone Methyltransferase
|
|
Ziftomenib (KO-539) is an inhibitor of menin-MLL interaction with antitumor activity and can be used to study leukemia. |
|
T69846 |
VTP50469 mesylate
|
|
|
|
VTP-50469 is a novel, potent, selective, orally-available MeninMLL1 inhibitor, being effectively against MLL-rearranged and NPM1c+ leukemia, selectively killing cell lines with MLLrearrangements and NPM1c+ mutations. |
|
T39769 |
DDO-2093
|
|
|
|
DDO-2093, a powerful inhibitor of the MLL1-WDR5 protein-protein interaction (IC50 = 8.6 nM; Kd = 11.6 nM), exhibits prominent antitumor effects. Notably, DDO-2093 selectively hampers the catalytic activity of the MLL com... |
|
T62915 |
Dot1L-IN-7
|
|
|
|
Dot1L-IN-7 (compound 25) is a selective and potent inhibitor of telomere silencing 1-like protein (DOT1L) (IC50: 1.0 μM).Dot1L-IN-7 selectively kills MLL-AF9 and does not affect the growth of E2A-HLF cells. |
|
T28269 |
ORY-1001 free base
|
RG 6016,ORY-1001,ORY 1001,ORY1001,RG-6016,RG6016 |
|
|
ORY-1001 is a KDM1A inhibitor (IC50 <20nM) with high selectivity against related FAD dependent aminoxidases (MAO-A/B, IL4I1, KDM1B >100uM, SMOX 7uM). Treatment of THP-1 (MLL-AF9) cells with ORY-1001, results in a time/do... |
|
T72239 |
DDO-2093 dihydrochloride
|
|
|
|
DDO-2093 dihydrochloride, a potent inhibitor of MLL1-WDR5 protein-protein interactions (IC50=8.6 nM; Kd=11.6 nM), exhibits antitumor activity. It selectively inhibits the catalytic activity of the MLL complex. |
